Insulet Corporation $PODD Shares Newly Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. purchased a new position in Insulet Corporation (NASDAQ:PODD) during the 3rd quarter, Holdings Channel reports. The fund purchased 21,136 shares of the medical instruments supplier’s stock, valued at approximately $2,758,000.

Several other large investors also recently added to or reduced their stakes in PODD. BlackRock Inc. bought a new stake in shares of Insulet during the second quarter valued at approximately $1,018,582,000. Arrowstreet Capital Limited Partnership lifted its holdings in Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after buying an additional 1,011,369 shares during the period. Man Group plc bought a new stake in shares of Insulet in the 2nd quarter valued at about $78,746,000. Amundi grew its stake in Insulet by 13.6% during the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock worth $77,320,000 after buying an additional 60,929 shares during the last quarter. Finally, Bank of America Corp DE acquired a new position in Insulet during the 2nd quarter valued at approximately $64,921,000.

Analyst Upgrades and Downgrades

Several analysts have commented on PODD shares. Jefferies Financial Group restated a “buy” rating and set a $200.00 price objective on shares of Insulet in a research note on Wednesday. Raymond James Financial reissued an “outperform” rating and issued a $180.00 price objective on shares of Insulet in a report on Thursday, August 6th. Leerink Partners upped their target price on Insulet from $143.00 to $167.00 and gave the stock a “market perform” rating in a research note on Thursday. Robert W. Baird set a $175.00 target price on Insulet in a report on Thursday, August 6th. Finally, BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Twelve investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $185.38.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

Insulet Price Performance

NASDAQ PODD traded down $9.61 during trading hours on Friday, reaching $146.51. The company’s stock had a trading volume of 1,567,721 shares, compared to its average volume of 1,380,594. The firm has a market capitalization of $10.16 billion, a price-to-earnings ratio of 23.86, a P/E/G ratio of 1.21 and a beta of 1.06. The company’s 50-day moving average is $141.97 and its two-hundred day moving average is $176.65. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, beating the consensus estimate of $1.59 by $0.40. The company had revenue of $842.00 million for the quarter, compared to analyst estimates of $832.63 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. Insulet’s quarterly revenue was up 19.2% compared to the same quarter last year. During the same period last year, the company earned $1.24 earnings per share. On average, equities analysts predict that Insulet Corporation will post 6.75 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.